Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus [Yahoo! Finance]
Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus
Sunshine Biopharma, Inc. (NASDAQ: SBFM) had its "buy" rating re-affirmed by analysts at Aegis. They now have a $15.00 price target on the stock.
Sunshine Biopharma Launches a New Generic Prescription Drug
Sunshine Biopharma Announces Breakthrough Research Results on the Company's K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepatocellular Carcinoma [Yahoo! Finance]